Generic Name and Formulations:
Ergocalciferol 1.25mg (50000 IU Vit. D); caps; contains tartrazine.
Indications for DRISDOL:
Hypoparathyroidism. Refractory rickets (also known as Vit. D resistant rickets). Familial hypophosphatemia.
Individualize. Vit. D resistant rickets: 12000 to 500000 IU units daily. Hypoparathyroidism: 50000 to 200000 IU units daily concomitantly with calcium lactate 4g, six times per day.
Hypercalcemia. Malabsorption syndrome. Abnormal sensitivity to toxic effects of Vit. D. Hypervitaminosis D.
Vit. D resistant rickets: range between therapeutic and toxic doses is narrow; obtain blood calcium and phosphorus levels every 2 weeks or more frequently if necessary. Ensure adequate dietary calcium intake. X-rays of the bones should be taken every month until condition is corrected and stabilized. Pregnancy (Cat.C). Nursing mothers.
Mineral oil interferes with Vit. D absorption. Concomitant thiazide diuretics in hypoparathyroid patients may cause hypercalcemia.
Vit. D analog.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Outcomes in SCCHN Improved With Swap of Docetaxel for 5-FU in Palliative Regimen
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|